United States

Albany Molecular Research Inc (AMRI.O)

AMRI.O on Nasdaq

28 Apr 2017
Change (% chg)

$-0.57 (-3.44%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low


Chart for AMRI.O


Albany Molecular Research, Inc. is a contract research and manufacturing company. The Company operates through Discovery and Development Services (DDS), Active Pharmaceutical Ingredients (API), Drug Product (DP) and Fine Chemicals (FC) segments. The DDS segment includes activities, such as drug lead discovery, optimization, drug... (more)


Beta: 1.33
Market Cap(Mil.): $687.34
Shares Outstanding(Mil.): 42.93
Dividend: --
Yield (%): --


  AMRI.O Industry Sector
P/E (TTM): -- 58.40 30.08
EPS (TTM): -1.83 -- --
ROI: -7.79 -0.42 13.25
ROE: -23.94 5.87 14.41

BRIEF-Albany Molecular Research enters into agreement with pharmaceutical group Ferrer, Accord Healthcare

* Albany Molecular Research Inc - entered into an agreement with pharmaceutical group Ferrer and Accord Healthcare, Inc.

Feb 21 2017

BRIEF-AMRI posts Q4 adj. earnings per share $0.34

* AMRI announces fourth quarter and full year 2016 results and provides 2017 outlook

Feb 21 2017

BRIEF-AMRI announces API agreement supply with Shire

* Has entered into a multi-year supply agreement for an undisclosed product with shire us manufacturing Source text for Eikon: Further company coverage:

Nov 29 2016

BRIEF-Amri Q3 non-gaap EPS $0.17

* Albany molecular research inc sees full year 2016 capital expenditures of approximately $48 million

Nov 08 2016

More From Around the Web

Earnings vs. Estimates